Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy

References

• Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-e181
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Clinical Practice Recommendations 2009. Diabetes Care 2009;32(Suppl. 1):S13-61
   PubMed Web of Science ®Google Scholar
• Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481-501
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CNB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• The 4S Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9
   PubMed Web of Science ®Google Scholar
• Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Treating to new target investigators. N Engl J Med 2005;352(14):1425-35
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-47
   PubMed Web of Science ®Google Scholar
• Rosuvastatin Prescribing Information. AstraZenneca Pharmaceuticals, LP, Wilmington, DE (02/2009)
   Google Scholar
• Ezetimibe/simvastatin, Prescribing Information. Merck/Schering-Plough Pharmaceuticals, North Wales, PA (01/2009)
   Google Scholar
• Jones PH, Hunninghake DB, Ferdinand KC, et al. Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004;26:1388-99
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Cannon CP, Morrow DA, et al.; for the PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 Substudy. JACC 2005;46:1411-16
   Google Scholar
• Baigent C, Keech A, Kearney PM, et al.; for the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in Lancet 2005;366:1358]. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Charland SL, McGovern ME, Stanek EJ. Diminishing rates of return in reducing coronary heart disease event rates with progressive LDL cholesterol lowering: linear vs inhibitory maximum effect modeling. Circulation 2005;112(Suppl. II):816
   Google Scholar
• Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19(Suppl. M):M8-14
   PubMedGoogle Scholar
• Nordestgaard BG, Benn M, Schnor P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
   PubMed Web of Science ®Google Scholar
• Stanek EJ, Sarawate C, Willey VJ, et al. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007;23:553-63
   PubMed Web of Science ®Google Scholar
• Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 1983;52:9B-12B
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. Am J Cardiol 1996;78:572-5
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
   PubMed Web of Science ®Google Scholar
• Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006;17:631-6
   PubMed Web of Science ®Google Scholar
• Niacin extended-release/Simvastatin, Prescribing Information. Abbott Laboratories, North Chicago, IL (08/2008)
   Google Scholar
• Niacin extended-release/Lovastatin, Prescribing Information. Abbott Laboratories, North Chicago, IL (08/2007)
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
   PubMed Web of Science ®Google Scholar
• Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol 2008;102:1654-62
   PubMed Web of Science ®Google Scholar
• Catapano A, Brady WE, King TR, et al. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared to rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Cur Med Res Opin 2005;21:1123-30
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61
   PubMed Web of Science ®Google Scholar
• Fellstrom BC, Jardine AG, Schmieder R, et al. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Kastelein JPJ, Akdim F, Stroes ESG, et al. for the ENHANCE investigators. N Eng J Med 2008;358:1431-43
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• IMPROVE-IT. NCT00202878. Available at: http://clinicaltrials.gov [Last accessed 8 July 2009]
   Google Scholar
• ARBITER 6-HALTS. NCT00397657. Available at: http://clinicaltrials.gov [Last accessed 8 July 2009]
   Google Scholar
• AIM-HIGH trial. NCT0020289. Available at: http://clinicaltrials.gov [Last accessed 8 July 2009]
   Google Scholar
• HPS2-THRIVE. NCT00461630. Available at: http://clinicaltrials.gov [Last accessed 8 July 2009]
   Google Scholar